Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments on the market that are injected weekly.
In one part of a Phase 1 trial where patients received a single dose, those on the highest dose of 2.4 milligrams experienced an average of 5.3% placebo-adjusted weight loss at one week, the company said Monday.
In the other part of the trial where patients received weekly doses for five weeks, those on the highest dose of 1.2 milligrams experienced 8.4% placebo-adjusted weight loss at the end of the five weeks.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
medical
Pendidikan
Pendidikan
Download Anime
Berita Teknologi
Seputar Teknologi
